Table 4 Distribution of the p53 mutations
From: MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1
Exon | Number of patients |
|---|---|
5 | 13 (9.2 %) |
6 | 9 (6.4 %) |
7 | 13 (9.2 %) |
8 | 18 (12.8%) |
Total | 53(37.6%) |
From: MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1
Exon | Number of patients |
|---|---|
5 | 13 (9.2 %) |
6 | 9 (6.4 %) |
7 | 13 (9.2 %) |
8 | 18 (12.8%) |
Total | 53(37.6%) |